Report

The brucellosis vaccine market is projected to register a CAGR of 6.2% during the forecast period (2022-2027).

The emergence of the COVID-19 pandemic had an adverse effect on the world economy and the healthcare system. The lockdown all over the globe has affected the supply chain of pharmaceuticals, medical devices, and biotechnological products both for humans and animals. For instance, according to the July 2021 report titled "Impact of COVID-19 on the delivery of veterinary services and animal disease reporting: (May-June 2020/June-August 2020)", the participants in both polls stated that COVID-19-related movement restrictions had been established in their home countries and had a detrimental effect on the operations of the veterinary services and in the first poll, 93% of respondents said COVID-19 had a negative impact on their veterinary services, and 70% said it was harder for field agents to carry out surveillance operations and field investigations. Hence, COVID-19 is expected to have a significant impact on the studied market, however, with the declining cases of COVID-19 and the opening of the world economy, the brucellosis vaccine market is expected to regain its full potential over the forecast period.

Brucellosis is one of the most widespread zoonoses transmitted by animals, and in endemic areas, human brucellosis has serious public health consequences. Expansion of animal industries and urbanization, and the lack of hygienic measures in animal husbandry and food handling, partly account for brucellosis remaining a public health hazard. For instance, according to an article published in November 2021, titled "Brucellosis: Epidemiology, Microbiology, Clinical Manifestations, and Diagnosis", an estimated 2.4 billion people are thought to be at risk of brucellosis, and there are roughly 500,000 cases reported annually around the world. Also, as per the same source, every age group is impacted and due to rising worldwide travel, trade, and migration, brucellosis is becoming more common thus, the demand for brucellosis vaccines is expected to grow over the forecast period. However, this number is likely underestimated as brucellosis cases are underreported and often misdiagnosed because symptoms are nonspecific, physicians may lack awareness, and laboratory capacity for diagnosis is limited. B. melitensis is the most frequently reported cause of human illness worldwide, while the most widespread potential source of infection is B. abortus. Hence, increasing the prevalence of the disease would increase the demand for a vaccine which would increase the market growth in the upcoming period.

The various initiatives the government and non-government organizations take to raise awareness about animal diseases, health, and protection propel the growth of the studied market over the forecast period. The government of different nations is introducing plans and guidelines for animal welfare. For Instance, in May 2021, United Kingdom Government introduced the first-ever action plan to improve the welfare and conservation of animals at home and abroad. The action plans include improvement and welfare programs for all animals, like incentivizing farmers to improve animal health and welfare through future farming policy. Such initiatives raise awareness about animal health and thus boost the market's growth. Furthermore, in Australia, the Animal Welfare Task Group developed animal welfare standards and guidelines for cattle and sheep. The national livestock identification system (NLIS), an electronic identification system in which each animal is tagged with a radiofrequency identification device, has been developed for cattle. Also, in September 2020, the international animal welfare organization World Animal Protection, along with National Disaster Response Force (NDRF) and other organizations and local communities, organized mobile veterinary treatment camps for animals affected by the floods in Assam. Thus, the studied market is expected to project growth over the forecast period due to the abovementioned factors. However, stringent regulation for animal vaccines is likely to hinder the market growth.

Brucellosis Vaccines Market Trends

Cattles Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Increasing cattle population and key developments like acquisitions by market players are expected to increase segmental growth. For instance, according to the January 2022 report of the United States Department of Agriculture (USDA), there were about 91.9 million cattle and calves in the United States. Similarly, according to the September 2021 report of the USDA, the population of cattle in India is expected to increase and reach 306.7 million in 2022. Hence, the increasing population of cattle is expected to drive demand for more brucellosis vaccines which is anticipated to boost the segment's growth.

Furthermore, many governments across the world are launching a brucellosis vaccination program for cattle and other animals to eradicate brucellosis which is further expected to have a significant positive impact on the studied market. For example, the Government of India is running a flagship scheme called the National Animal Disease Control Program (NADCP) to control foot and mouth disease (FMD) and Brucellosis by vaccinating 100% cattle, buffalo, sheep, goat, and pig population for FMD and 100% bovine female calves of 4-8 months of age for brucellosis over five years period of 2019-2024 with a budget of INR 13,343 crore. Therefore, owing to the above-mentioned factors, the cattle segment is expected to have a significant share in the brucellosis vaccines market over the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

The North American region is expected to have a significant share in the brucellosis vaccines market owing to the factors such as the presence of a large animal population, high burden of brucellosis and increasing awareness about animal health, and the presence of key market players in the region, along with other factors. For instance, as per the January 2022 estimates by Statistics Canada, cattle, and calf slaughter for the period from July to December 2021 was up 0.7% from the same period in 2020 and reached the highest level seen since the second half of 2009 and as of January 1, 2022, Canadian farmers had 11.1 million cattle and calves on their farm.

Further, as per the 2022 update of the United States Department of Agriculture, commercial beef production in the United States is increased over the years totaling 27.6 billion pounds in 2020, with a total value of USD 6.8 billion and this data shows high production and increasing demand for meat products which is expected to have a significant impact on the studied market in the region. Further, the ongoing research and development activities along with new developments from the key market players in the region are expected to boost the market growth. For instance, according to a research study published in July 2021, titled "Immune Responses and Efficacy of Brucella Abortus Strain RB51 in Bison After Delivery in a Dry Dart Formulation or by Parenteral Inoculation", while statistically stronger than in control animals, the humoral responses against RB51 induced by the dry dart formulation appear to be less pronounced on the ELISA than those induced by parenteral vaccination of bison and these reactions are also transient because they are only seen 4 and 8 weeks after the initial vaccination, and thus, positive results from studies like these are further expected to impact the market's growth. Therefore, owing to the above-mentioned factors, the brucellosis vaccine market is expected to grow over the forecast period of the study in the North American region.

Brucellosis Vaccines Market Competitor Analysis

Most players are based in developing counties due to more technological advancements. But due to the ease of connectivity in modern times, these players have also penetrated developing countries and are trying to establish a market. The market is partially fragmented which makes it moderately competitive. Some companies currently dominating the market are Merck & Co., Inc., Ceva, CZ Vaccines, Laboratories Tornel, and Hester Biosciences Limited, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format


• 3 months of analyst support